KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Goodwill & Intangibles (2016 - 2019)

Arbutus Biopharma's Goodwill & Intangibles history spans 7 years, with the latest figure at $66.3 million for Q2 2019.

  • On a quarterly basis, Goodwill & Intangibles fell 18.26% to $66.3 million in Q2 2019 year-over-year; TTM through Jun 2019 was $66.3 million, a 18.26% decrease, with the full-year FY2018 number at $66.3 million, down 20.12% from a year prior.
  • Goodwill & Intangibles hit $66.3 million in Q2 2019 for Arbutus Biopharma, roughly flat from $66.3 million in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for ABUS hit a ceiling of $546.1 million in Q2 2015 and a floor of $66.3 million in Q3 2018.
  • Historically, Goodwill & Intangibles has averaged $242.1 million across 5 years, with a median of $123.8 million in 2016.
  • The widest YoY moves for Goodwill & Intangibles: up 5.57% in 2016, down 75.97% in 2016.
  • Tracing ABUS's Goodwill & Intangibles over 5 years: stood at $515.2 million in 2015, then tumbled by 75.97% to $123.8 million in 2016, then plummeted by 32.95% to $83.0 million in 2017, then fell by 20.12% to $66.3 million in 2018, then changed by 0.0% to $66.3 million in 2019.
  • Business Quant data shows Goodwill & Intangibles for ABUS at $66.3 million in Q2 2019, $66.3 million in Q1 2019, and $66.3 million in Q4 2018.